Dear Clinician: Immune checkpoint inhibitors (ICIs) are the most commonly used type of cancer immunotherapy. Unfortunately, these agents can cause a number of immune-related adverse […]
Educational Partnerships
Educational Partnership: Updates in RA, PsA, and Biosimilars: A Pipeline View for the Clinical Nurse
Authors: Linda Grinnell-Merrick, NP-BC; Carrie Beach, BSN, RN-BC; Eileen Lydon, MA, RN, ANP-BC; Elizabeth Kirchner, MSN, CNP CE Released: 12/26/2018 Valid for credit through: 12/26/2019 […]